2，6-二异丙基苯酚衍生物抗瘤活性研究
|
摘要
第一部分2,6-二异丙基苯酚衍生物对人乳癌细胞的影响
目的:观察2,6-二异丙基苯酚衍生物对人乳癌细胞增殖及凋亡的影响
方法:体外培养人乳癌细胞株MDA-MB-231,实验分为8组:①正常对照组,②空白对照组,③紫杉醇对照组,2,6-二异丙基苯酚衍生物不同浓度干预组,④50μM,⑤100μM,⑥200μM,⑦400μM,⑧600μM。各实验组干预后继续培养24、48、72小时后待查。采用MTT法选择最佳细胞接种浓度、培养时间及最适抑制浓度,计算其IC50值。观察各组瘤细胞形态变化及增殖情况,采用流式细胞仪观察各组瘤细胞凋亡情况。
结果:①MTT法发现人乳癌细胞株MDA-MB-231最佳接种浓度为5.0×10~4/ml,加药时间为接种细胞后24小时。
②2,6-二异丙基苯酚衍生物最适抑制浓度为400ug/ml,IC50为390.3 ug/ml。
③正常对照组及空白对照组瘤细胞形态及生长增殖情况在各时间段前后无变化。
④紫杉醇对照组在48小时后有大量坏死细胞,与2,6-二异丙基苯酚衍生物400μM及600μM浓度组比较,差异不显著(P＞0.05)。
⑤各浓度干预组在24小时前后瘤细胞形态及生长增殖情况无变化;200μM浓度组在48小时后可见部分死亡瘤细胞,细胞生长受到抑制,与50μM、100μM组比较,差异显著(P＜0.05);400μM及600μM浓度组在48小时后可见大量死亡瘤细胞,细胞生长受到明显抑制,与50μM、100μM、200μM组间比较,差异非常显著(P＜0.01),400μM与600μM组间差异不显著。
结论:2,6-二异丙基苯酚衍生物具有抗人乳癌细胞株MDA-MB-231活性。
第二部分2,6-二异丙基苯酚衍生物对人神经母细胞瘤细胞及肝癌细胞的影响
目的:观察2,6-二异丙基苯酚衍生物对人神经母细胞瘤及肝癌细胞的影响
方法:体外分别培养人神经母细胞瘤细胞株和肝癌细胞株。把第一部分紫杉醇对照组换为羟基喜树碱对照组,其余实验分组方法、对照组及干预组浓度设计、时段设置和观察指标同第一部分。
结果:①MTT法发现人神经母细胞瘤细胞株及肝癌细胞株最佳接种浓度为5.0×10~4/ml,加药时间为接种细胞后24小时。
②神经母细胞瘤最适抑制浓度为200ug/ml,IC50为268.2 ug/ml。肝癌细胞最适抑制浓度为200ug/ml,IC50为185.5ug/ml。
③正常对照组及空白对照组瘤细胞形态及生长增殖情况在各时间段两种肿瘤细胞均无变化。
④神经母细胞瘤细胞组48小时后,200μM、400μM、600μM组吸光度值与50μM、100μM组比较有非常显著性差异(P＜0.01)。200μM与400μM组比较无显著性差异(P＞0.05),400μM与600μM组比较有显著性差异(P＜0.05)。羟基喜树碱对照组与200μM与400μM组比较无显著性差异(P＞0.05),与600μM组比较有非常显著性差异(P＜0.01)。
⑤肝癌细胞组48小时后,50μM组与正常对照组和空白对照组吸光度值比较无显著性差异(P＞0.05)。100μM、200μM、400μM、600μM组吸光度值与50μM组、对照组比较有非常显著性差异(P＜0.01)。100μM、200μM、400μM组与600μM组比较有非常显著性差异(P＜0.01)。羟基喜树碱对照组与100μM与200μM组比较无显著性差异(P＞0.05),与400μM组比较有显著性差异(P＜0.05),与600μM组比较有非常显著性差异(P＜0.01)。
⑥两种肿瘤细胞在100μM浓度组间比较,差异非常显著(P＜0.01)。
结论:2,6-二异丙基苯酚衍生物具有抗人神经母细胞瘤和肝癌细胞活性,但对抗肝癌细胞表现更佳。
PART 1 EFFECTS OF 2,6-DIISOPROPYL PHENOL DERIVATIVES ON HUMAN BREAST CANCER CELLS
Objective:To observe the effects of 2,6-diisopropyl phenol derivatives on proliferation and apoptosis of human breast cancer cells.
Methods:Breast cancer cell lines MDA-MB-231 were cultured in vitro.There were 8 groups in the experiment:cell control group,solvent control group(0.5%DMSO),paclitaxel control group,different concentration experimental group of 2,6-diisopropyl phenol derivatives at 50μM,100μM,200μM,400μM and 600μM.Each experimental group continued to be cultured for 24 hours after intervention in order to be investigated.Optimal cell innovulation concentration and culture time were chosen with the application of MTT assay;detecting morphologic change and proliferation condition of tumor cells in each group and then observing every group's apoptosis of tumor cells with flow cytometer.
Results:(1)The optimal innoculation concentration of human breast cancer cell line MDA-MB-231 was found to be 5.0×10~4/ml and the administration timing of drug should be 24 hours after inoculating cells with MTT assay.
(2)There was no morphologic change or proliferation condition change of tumor cells in cell control and solvent control groups within 24 hours.
(3)Lots of necrotic cells were observed in hydrocamptothecin control group,compared with 2,6-diisopropyl phenol derivatives at 400μM and 600μM concentration groups,the difference was not significant (P＞0.05).
(4)No morphologic change or proliferation condition change of tumor cells was found in 2,6-diisopropylphenol derivatives at 50μM and 100μM concentration groups within 24 hours.Part of dead tumor cells were observed and some cells underwent apoptosis in 200μM concentration group,compared with 50μM and 100μM groups,the difference was remarkable(P＜0.05);In 400μM and 600μM concentration groups,there were a big amount of dead tumor cells after 24 hours,lots of tumor cells underwent apoptosis,compared with 50μM,100μM and 200μM groups,the differences were quite significant(P＜0.01),group comparsion between 400μM and 600μM showed that the difference was not significant.
Conclusion:2,6-diisopropylphenol derivatives have the activity to resist human breast cancer cell line MDA-MB-231.
PART 2 EFFECTS OF 2,6-DIISOPROPYLPHENOL DERIVATIVES ON HUMAN NEUROBLASTOMA CELLS AND HEPATOMA CARCINOMA CELLS
Objective:To detect effects of 2,6—diisopropylphenol derivatives on human neuroblastoma cells and hepatoma carcinoma cells.
Methods:Human neuroblastoma cell lines and hepatoma carcinoma cell lines were cultured in vitro sepreately.Paclitaxel control group in part 1 changed to hydroxycamptothecin control group in part 2.The other of experimental groups,concentration and time controlled,and detecting part same as part 1.
Results:(1)The optimal innoculation concentration of human neuroblastoma cell lines and hepatoma carcinoma cell lines was found to be 5.0×10~4/ml and the administration timing of drug should be 24 hours after inoculating cells with MTT assay.
(2)There was no morphologic change or proliferation condition change of tumor cells in cell control and solvent control groups within 24 hours.
(3)Absorbance values of neuroblastoma cell group,200μM,400μM and 600μM groups had significant difference with that of 50μM and 100μM groups(P＜0.01).Group comparsion between 200μM and 400μM groups showed no sifnificant difference(P＞0.05).Comparsion between 400μM and 600μM groups had obvious difference.Compared with 200μM and 400μM groups,hydroxycamptothecin control group had no remarkable difference(P＞0.05),however,when compared with 600μM group,the difference was significant(P＜0.01)
(4)Hepatoma carcinoma cell group and 50μM group had no significant difference with cell control group and solvent control group in absorbance values(P＞0.05).Absorbance values of 100μM,200μM,400μM and 600μM groups had very significant difference with that of 50μM group and contol group(P＜0.01).There was significant difference between 600μM group and 100μM,200μM,400μM groups(P＜0.01).Compared with 100μM and 200μM groups,hydroxycamptothecin control group had no obvious difference(P＞0.05),when compared with 400μM group,the difference was significant(P＜0.05),as compared with 600μM group,the difference was quite remarkable(P＜0.01)
(5)Group comparsion between two kinds of tumor cells at 100μM concentration showed significant difference(P＜0.01)
Conclusion:2,6-diisopropyl phenol derivatives have the activity to resist human neuroblastoma cells and hepatoma carcinoma cells,but the effect of anti-hepatoma carcinoma cell is better.
目的:观察2,6-二异丙基苯酚衍生物对人乳癌细胞增殖及凋亡的影响
方法:体外培养人乳癌细胞株MDA-MB-231,实验分为8组:①正常对照组,②空白对照组,③紫杉醇对照组,2,6-二异丙基苯酚衍生物不同浓度干预组,④50μM,⑤100μM,⑥200μM,⑦400μM,⑧600μM。各实验组干预后继续培养24、48、72小时后待查。采用MTT法选择最佳细胞接种浓度、培养时间及最适抑制浓度,计算其IC50值。观察各组瘤细胞形态变化及增殖情况,采用流式细胞仪观察各组瘤细胞凋亡情况。
结果:①MTT法发现人乳癌细胞株MDA-MB-231最佳接种浓度为5.0×10~4/ml,加药时间为接种细胞后24小时。
②2,6-二异丙基苯酚衍生物最适抑制浓度为400ug/ml,IC50为390.3 ug/ml。
③正常对照组及空白对照组瘤细胞形态及生长增殖情况在各时间段前后无变化。
④紫杉醇对照组在48小时后有大量坏死细胞,与2,6-二异丙基苯酚衍生物400μM及600μM浓度组比较,差异不显著(P＞0.05)。
⑤各浓度干预组在24小时前后瘤细胞形态及生长增殖情况无变化;200μM浓度组在48小时后可见部分死亡瘤细胞,细胞生长受到抑制,与50μM、100μM组比较,差异显著(P＜0.05);400μM及600μM浓度组在48小时后可见大量死亡瘤细胞,细胞生长受到明显抑制,与50μM、100μM、200μM组间比较,差异非常显著(P＜0.01),400μM与600μM组间差异不显著。
结论:2,6-二异丙基苯酚衍生物具有抗人乳癌细胞株MDA-MB-231活性。
第二部分2,6-二异丙基苯酚衍生物对人神经母细胞瘤细胞及肝癌细胞的影响
目的:观察2,6-二异丙基苯酚衍生物对人神经母细胞瘤及肝癌细胞的影响
方法:体外分别培养人神经母细胞瘤细胞株和肝癌细胞株。把第一部分紫杉醇对照组换为羟基喜树碱对照组,其余实验分组方法、对照组及干预组浓度设计、时段设置和观察指标同第一部分。
结果:①MTT法发现人神经母细胞瘤细胞株及肝癌细胞株最佳接种浓度为5.0×10~4/ml,加药时间为接种细胞后24小时。
②神经母细胞瘤最适抑制浓度为200ug/ml,IC50为268.2 ug/ml。肝癌细胞最适抑制浓度为200ug/ml,IC50为185.5ug/ml。
③正常对照组及空白对照组瘤细胞形态及生长增殖情况在各时间段两种肿瘤细胞均无变化。
④神经母细胞瘤细胞组48小时后,200μM、400μM、600μM组吸光度值与50μM、100μM组比较有非常显著性差异(P＜0.01)。200μM与400μM组比较无显著性差异(P＞0.05),400μM与600μM组比较有显著性差异(P＜0.05)。羟基喜树碱对照组与200μM与400μM组比较无显著性差异(P＞0.05),与600μM组比较有非常显著性差异(P＜0.01)。
⑤肝癌细胞组48小时后,50μM组与正常对照组和空白对照组吸光度值比较无显著性差异(P＞0.05)。100μM、200μM、400μM、600μM组吸光度值与50μM组、对照组比较有非常显著性差异(P＜0.01)。100μM、200μM、400μM组与600μM组比较有非常显著性差异(P＜0.01)。羟基喜树碱对照组与100μM与200μM组比较无显著性差异(P＞0.05),与400μM组比较有显著性差异(P＜0.05),与600μM组比较有非常显著性差异(P＜0.01)。
⑥两种肿瘤细胞在100μM浓度组间比较,差异非常显著(P＜0.01)。
结论:2,6-二异丙基苯酚衍生物具有抗人神经母细胞瘤和肝癌细胞活性,但对抗肝癌细胞表现更佳。
PART 1 EFFECTS OF 2,6-DIISOPROPYL PHENOL DERIVATIVES ON HUMAN BREAST CANCER CELLS
Objective:To observe the effects of 2,6-diisopropyl phenol derivatives on proliferation and apoptosis of human breast cancer cells.
Methods:Breast cancer cell lines MDA-MB-231 were cultured in vitro.There were 8 groups in the experiment:cell control group,solvent control group(0.5%DMSO),paclitaxel control group,different concentration experimental group of 2,6-diisopropyl phenol derivatives at 50μM,100μM,200μM,400μM and 600μM.Each experimental group continued to be cultured for 24 hours after intervention in order to be investigated.Optimal cell innovulation concentration and culture time were chosen with the application of MTT assay;detecting morphologic change and proliferation condition of tumor cells in each group and then observing every group's apoptosis of tumor cells with flow cytometer.
Results:(1)The optimal innoculation concentration of human breast cancer cell line MDA-MB-231 was found to be 5.0×10~4/ml and the administration timing of drug should be 24 hours after inoculating cells with MTT assay.
(2)There was no morphologic change or proliferation condition change of tumor cells in cell control and solvent control groups within 24 hours.
(3)Lots of necrotic cells were observed in hydrocamptothecin control group,compared with 2,6-diisopropyl phenol derivatives at 400μM and 600μM concentration groups,the difference was not significant (P＞0.05).
(4)No morphologic change or proliferation condition change of tumor cells was found in 2,6-diisopropylphenol derivatives at 50μM and 100μM concentration groups within 24 hours.Part of dead tumor cells were observed and some cells underwent apoptosis in 200μM concentration group,compared with 50μM and 100μM groups,the difference was remarkable(P＜0.05);In 400μM and 600μM concentration groups,there were a big amount of dead tumor cells after 24 hours,lots of tumor cells underwent apoptosis,compared with 50μM,100μM and 200μM groups,the differences were quite significant(P＜0.01),group comparsion between 400μM and 600μM showed that the difference was not significant.
Conclusion:2,6-diisopropylphenol derivatives have the activity to resist human breast cancer cell line MDA-MB-231.
PART 2 EFFECTS OF 2,6-DIISOPROPYLPHENOL DERIVATIVES ON HUMAN NEUROBLASTOMA CELLS AND HEPATOMA CARCINOMA CELLS
Objective:To detect effects of 2,6—diisopropylphenol derivatives on human neuroblastoma cells and hepatoma carcinoma cells.
Methods:Human neuroblastoma cell lines and hepatoma carcinoma cell lines were cultured in vitro sepreately.Paclitaxel control group in part 1 changed to hydroxycamptothecin control group in part 2.The other of experimental groups,concentration and time controlled,and detecting part same as part 1.
Results:(1)The optimal innoculation concentration of human neuroblastoma cell lines and hepatoma carcinoma cell lines was found to be 5.0×10~4/ml and the administration timing of drug should be 24 hours after inoculating cells with MTT assay.
(2)There was no morphologic change or proliferation condition change of tumor cells in cell control and solvent control groups within 24 hours.
(3)Absorbance values of neuroblastoma cell group,200μM,400μM and 600μM groups had significant difference with that of 50μM and 100μM groups(P＜0.01).Group comparsion between 200μM and 400μM groups showed no sifnificant difference(P＞0.05).Comparsion between 400μM and 600μM groups had obvious difference.Compared with 200μM and 400μM groups,hydroxycamptothecin control group had no remarkable difference(P＞0.05),however,when compared with 600μM group,the difference was significant(P＜0.01)
(4)Hepatoma carcinoma cell group and 50μM group had no significant difference with cell control group and solvent control group in absorbance values(P＞0.05).Absorbance values of 100μM,200μM,400μM and 600μM groups had very significant difference with that of 50μM group and contol group(P＜0.01).There was significant difference between 600μM group and 100μM,200μM,400μM groups(P＜0.01).Compared with 100μM and 200μM groups,hydroxycamptothecin control group had no obvious difference(P＞0.05),when compared with 400μM group,the difference was significant(P＜0.05),as compared with 600μM group,the difference was quite remarkable(P＜0.01)
(5)Group comparsion between two kinds of tumor cells at 100μM concentration showed significant difference(P＜0.01)
Conclusion:2,6-diisopropyl phenol derivatives have the activity to resist human neuroblastoma cells and hepatoma carcinoma cells,but the effect of anti-hepatoma carcinoma cell is better.
引文
[1] Tsuchiya M, Asada A, Maeda K, Ueda Y, Sato EF, Shindo M, Inoue M. Propofol versus midazolam regarding their antioxidant activities. Am J Respir Crit Care Med 2001,163:26-31.
[2] Kanaya N, Gable B, Murray PA, Damron DS. Propofol increases phosphorylation of troponin 1 and myosin light chain 2 via protein kinase C activation in cardiomyocytes. Anesthesiology 2003,98:1363-1371.
[3] Mammoto T, Mukai M, Mammoto A, Yamanaka Y, Hayashi Y, Mashimo T, Kishi Y, Nakamura H. Intravenous anesthetic propofol inhibits invasion of cancer cells. Cancer Lett 2002,184:165-170.
[4] Tsuchiya M, Asada A, Arita K, Utsumi T, Yoshida T, Sato EF, Utsumi K, Inoue M. Induction and mechanism of apoptotic cell death by propofol in HL-60 cells. Acta Anaesthesiol Scand 2002,46:1068-1074.
[5] Rafat A Siddiqui,Mustapha Zerouga,Min Wu, et al . Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Research 2005,7:R645-R654.
[1]王红阳,丁劲,冯赘.细胞信号转导与靶向抗肿瘤药物的研发.中国肿瘤生物治疗杂志,2007,14(1):401-4.
[2]Ng YY,Hall-Craggs MA,Dicks-Mireaux C,et al.Wilms' tumour:pre-and post-chemotherapy CT appearances.Clinic Radiol,1991,43:255-9.
[3]Slapak CA,Kufe DW.Principles of cancer therapy[M]//Issel-bacher KJ.Harrison s principles of internal medicine.14 th ed.New York:McGraw-Hill,1988:523-537.
[4]Speake G,Holloway B.Costello G.Recent developments related to the EGFR as a target for cancer chemotherapy[J].Curr Opin Pharmacol,2005,5(4):343-349.
[5]Johnson GL.Dohlman HG.Graves LM.MAPK kinase kinases(MKKKs)as a target class for small-molecule inhibition to modulate signaling networks and gene expression[J].Curt Opin ChemBiol,2005,9(3):325-331.
[6]Mitsiades CS,Mitsiades N,Koutsilieris M,et al.The Akt pathway:molecular targets for anti-cancer drug development[J].Curr cancer Drug Targets,2004,4(3):235-256.
[7]Muller AJ,Young JC,Pendergast AM,et al.BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase onco-gene of Philadepia chromosome-posi-tive human leukemias[J].Mol Cell Biol,1991,11(4):1785-1792.
[8]Deininger MW,Goldman JM,Melo JV.The molecular biology of chronic myeloid leukemia[J].Blood,2000,96(10):3343-3356.
[9]Gorre ME,Mohammed M,Ellwood K et al.Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or anl-plification[J].Science,2001,293(5531):876-880.
[10]Adjei AA,Molina JR,Mandrekar SJ,et al.Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer[J].Clin Cancer Res.2007,13(9):2684-691.
[11]Wolter P,Dumez H,Schtffski P.Sunitinib and hypothyroidism[J].N Engl J Med,2007,356(15):1580.
[12]Tsuchiya M,Asada A,Maeda K,Ueda Y,Sato EF,Shindo M,Inoue M:Propofol versus midazolam regarding their antioxidant activities.Am J Respir Crit Care Med 2001,163:26-31.
[13]Kanaya N,Gable B,Murray PA,Damron DS:Propofol increases phosphorylation of troponin 1 and myosin light chain 2 via protein kinase C activation in cardiomyocytes.Anesthesiology 2003,98:1363-1371.
[14]Tsuchiya M,Asada A,Arita K,Utsumi T,Yoshida T,Sato EF,Utsumi K,Inoue M:Induction and mechanism of apoptotic cell death by propofoi in HL-60 cells.Acta Anaesthesiol Scand 2002;46:1068-1074.
[15]Rafat A Siddiqui,Mustapha Zerouga,Min Wu,et al:Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells.Breast Cancer Research 2005,7:R645-R654.
[16]陆永奎,胡晓桦,李永强,等。以紫杉醇为主的联合化疗方案治疗转移性乳腺癌的临床研究[J].现代肿瘤医学,2006,14(3):279-281.
[17]胥彬。抗癌药物研究的新进展[J].实用肿瘤杂志,2001,16(5):289-291.
[18]Broker LE,HuismanC,Span SW,et al.Cathepsin B hiediales caspase-independent cell death induced by micmtubule slabilizing agents in non-small cell lung cancer cells[J].Cancer Res,2004,64(1):27-30.
[19]DiLeo A.The European experience with docetaxel in the treatment of early-stage breast cancer[J].Clin Breast Cancer,2002,3(suppl 2):S59-62.
[20]Steams V,Singh B,Tsangaris T,et al.A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer[J].Clin Cancer Res,2003,9(1):124-133.
[21]SudaT,Takahashi T,Golstein P,et al.Moleculor Cloning and expression of the Fas ligand,a novel member of the tumor necrosis factor family[J].Cell,1993,75(6):1169-1178.
[22]Gebbia V, Blasi L, Borsellino N, et al. Paclitaxel and epidox orubicin or doxorubicin versus cyclophosphamide and epidox orubicin as first-line chemot chemotherapy for metastatic breast carcinoma: a randomised phase II study [J]. Anticancer Res, 2003, 23 (IB): 765-771.
[1]Bowman LC,Hancock MI,Santana VM,et al.Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma.,the St- Jude Children's Research Hospital experience,1962 to 1988[J],J Clin Oncol,1991,9:1599.
[2]高解春.小儿晚期恶性肿瘤延期和二次手术的指征和时机[J].中华小儿外科杂志,1995,16:295.
[3][3]江启俊.外科治疗神经母细胞瘤的世纪回顾及展望[J].中华小儿外科杂志,2000,21:137.
[4]凯,高解春.神经母细胞瘤的治疗进展[J].中华小儿外科科杂志,2002,23:169.
[5]Ikuta K.Cord blood stem cell transplantation and cord blood bank[J].Nippon Rinsho,1998,56(2):521.
[6]Ferrari N,Pfahl M,Levi G,et al.Retinoic acid receptor gammal(RAR)levels control RARbeta2 expression in SK-N-BE2 neuroblastoma cells and regulate a differentiation apoptosis switch[J].Mol Cell Biol,1998,18:6482.
[7]Moore TB,Koeffer HP,Yamashiro JM,et al.Vitamin D3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells[J].Clin Exp Metastasis,1996,14(3):239.
[8]Lorence RM,Reichard KW,Katubig BB,et al.Cornplete regression of human neuroblastoma xenografts in athymic mice after local newcastle disease Virus,ther-apy[J].J Natl Cancer Inst,1994,86(16):1228.
[9]Evans AE,Silber JH,Shpilsky A,et al.Successful management of low-stage neuroblastoma without adjuvant therapies:a comparison of two decades,1972through 1981 and 1982 through 1992,in a single institution[J].J Clin Oncol,1996,14(9):2504.
[10]Marsh JW,Geller DA,Finkelstein SD,et al.Role of liver transplantation for hepatobiliary malignant disorders[J].Oncology,2004,5(8):480-488.
[11]钦伦秀,孙惠川,汤钊猷.原发性肝癌研究进展[J].China J Surg,2006.44(15): 1070.
[12]Eaton DL,Kamsdell HS.Species and diet related diferences in plied mycology [M].V01 V.New York:Academic Press,1991.322.
[13]汤钊猷,余业勤.原发性肝癌[M].上海:上海科学技术出版社。1999.334.
[14]龚国忠,蒋永芳,朱映华.丙型肝炎病毒Ns 5A对p53活性调控机制研究[J].中华肝脏病杂志,2003,11(3):162.
[15]俞顺章,赵宁,资晓林.饮水中微囊藻毒素与我国原发性肝癌关系的研[J].中华肿瘤杂志,2001,23(2):96。
[16]Tran TT,Nissen N,Poordad FF,et al,Advances in liver transplantation.New strategies and current care expand access,enhance survival[J].Postgrad Med,2004,115(5):73-76.
[17]吴孟超,陈汉,沈峰.原发性肝癌的外科治疗.附5524例报告[J].中华外科杂志,2001,39(1):25-28。
[18]Schwarz RE,Smith DD.Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population[J].Am J Surg,2008,4(22):
[1]王红阳,丁劲,冯赘。中国肿瘤生物治疗杂志,Vol.14 No.5 Oet.2007,401-404。
[2]孙燕.积极提高医学临床研究的质量.中华肿瘤防治杂志.2006;13(2):81-83。
[3]储大同.肿瘤分子靶向治疗的进展及问题.临床肿瘤学杂志2006;11:1-6。
[4]Westerhoff HV,Palsson B0.The evolution of molecular biology into systems biology[J].Nat Biotechnol,2004,22(10):1249-1252.
[5]Wolf B,Brischwein M,Lob V.Cellular signaling.,aspects for tumor diagnosis and therapy[J].Biomed Yech(Berl),2007,52(1):164-168.
[6]Binetruy B,Heasley L,Bast F,et al.Concise review.,regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases[J].Stem Cells,2007,25(5):1090-1095.
[7]Huang C,Jacobson K,Schaller MD.MAP kinases and cell migration[J].J Cell Sci,2004,1179(20):4619-4628.
[8]Wu WS.The signaling mechanism of ROS in tumor progression[J].Cancer Metastasis Rev,2006,25(4):695-705.
[9]Polakis P.Wnt signaling and cancer[J].Genes Dev,2000,14:1837-1851.
[10]Lustig B,Behrens J.The Writ signaling pathway and its role in tumor development [J].J Cancer Res Clin Oncol,2003.129(4):199-221.
[11]Major MB,Camp ND,Berndt JD,et al.Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling[J],science,2007,316(5827):1043-1046.
[12]Perkins ND.Integrating cell-signalling pathways with NF-kappaB and IKK function[J].Nat Rev Mol Cell Biol,2007,8(1):49-62.
[13]Schulze-Luehrmann J,Ghosh S.Antigen-receptor signaling to nuclear factor kappa B[J].Immunity,2006,25(5):701-715.
[14]Derynck R,Akhurst RJ,Balmain A.TGF-beta signaling in tumor suppression and cancer progression[J].Nat Genet,2001,29(2):117-129.
[15]Slapak CA,Kufe DW.Principles of cancer therapy[M]//Issel-bacher KJ.Harrison's principles of internal medicine.14 th ed.New York:McGraw-Hill, 1988:523-537.
[16]Motzer JR,Hutson TE,Tomczak P,et al.Phase Ⅲ rand omized trial of sunitinib malate(SU1 1 2 4 8)ver su s interferon-alfa(IFN-α)a s first-1 in esys temic the rapy for patients with metastatic rena 1 cell carcinoma(mRCC)Proc ASCO 2005;24:LBA36.
[17]孙燕、何友兼、许立功,等.美罗华治疗B细胞淋巴瘤Ⅱ期临床验证报告。中国新药杂志1999;8(12):822-4.
[18]孙燕、李丽庆、宋三泰,等.注射用曲妥珠单抗治疗晚期乳腺癌临床验证报告。中华肿瘤杂志2003:25:581-3.
[19]Kumar R,Shepard HM,Mendelsohn J.Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoelonal antibody and serum growth factor(s)in human mammary carcinoma cells[J].Mol Cell Biol,1991,11(2):979-986.
[20]Molina MA,Codony-Servat J,Albanell J,et al.Trastuzumab(herceptin),a humanized anti-Her2 receptor monoclonal antibody,inhibits basal and activated Her2 ectod-omain cleavage in breast cancer cells[J].Cancer Res,2001,61(12):4744-4749.
[21]Pieeart-Gebha rt MJ,Protcer M,Leyland-Jones B,et al.Trastuzum abafter adjuvant chemo therapy in HER2-positive breast cancer.New Engl J Med2005;353(16):1660-72.
[22]Lin NU,Carey LA,Liu MC,e t al.Phase Ⅱ trial ofla p at in ib for b rainme s tatas es in patients with HER2+ breast cancer.Pr oc ASCO 2006;24:503a.
[23]Kelly H,Gold berg RM.Systemic therapy for metastatic co lo rectal cancer:current options,current evidence.J Clin Onco 12005 Ju 110;23(20):4553-60.
[24]J.B.Vermorken,J.Bourhis,J.Trigo,et a l.Cetuximab in re-current/metastatic (R&M)squamous cell carcinoma of the head and neck(SCCHN)refractory to first -line platinum-based therapies.Proc Am Soc Cl in On col2005;23(16s):5505.
[25]王华庆、沈芸.分子靶向药物贝伐单抗研究进展。中国肿瘤2005;14:716-9.
[26]Berry SR,Cunningham D,Michail M,e t al.Preliminary safety of bevacizumab with first-line Folfox,Capox,F olfe ri an d cap ec ta b in e for mCRC-First BRA trial.Proc ASCO 2006;24:3534a.
[27]Deininger MW,Goldman JM,Lydon N,et al.The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells[J].Blood.1997,90(9):3691-3698.
[28]Druker BJ,Sawyers CL,Kantarjian H et al.Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome[J].N Engl J Med,2001,34(14)1038-1042.
[29]Kantarjian HM.Cortes JE.O Brien S et al.Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferonalpha[J].Blood,2004,104(7):1979.1988
[30]王金万、孙燕、刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC 随机、双盲、对照、多中心Ⅲ期临床研究。中国肺癌杂志2005;8:283-290.
[31]张芷旋,周清华.中药抗肺癌血管生成药物的研究进展.中国肺癌杂志,2006:96-99.
[32]Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoelonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,34(11):783-792.
[33]van't Veer LJ,Dai H,van de Vijver MJ,et al.Gene expression profiling predicts clinical outcome of breast cancer[J].Nature,2002,415(6871):530-536.
[2] Kanaya N, Gable B, Murray PA, Damron DS. Propofol increases phosphorylation of troponin 1 and myosin light chain 2 via protein kinase C activation in cardiomyocytes. Anesthesiology 2003,98:1363-1371.
[3] Mammoto T, Mukai M, Mammoto A, Yamanaka Y, Hayashi Y, Mashimo T, Kishi Y, Nakamura H. Intravenous anesthetic propofol inhibits invasion of cancer cells. Cancer Lett 2002,184:165-170.
[4] Tsuchiya M, Asada A, Arita K, Utsumi T, Yoshida T, Sato EF, Utsumi K, Inoue M. Induction and mechanism of apoptotic cell death by propofol in HL-60 cells. Acta Anaesthesiol Scand 2002,46:1068-1074.
[5] Rafat A Siddiqui,Mustapha Zerouga,Min Wu, et al . Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells. Breast Cancer Research 2005,7:R645-R654.
[1]王红阳,丁劲,冯赘.细胞信号转导与靶向抗肿瘤药物的研发.中国肿瘤生物治疗杂志,2007,14(1):401-4.
[2]Ng YY,Hall-Craggs MA,Dicks-Mireaux C,et al.Wilms' tumour:pre-and post-chemotherapy CT appearances.Clinic Radiol,1991,43:255-9.
[3]Slapak CA,Kufe DW.Principles of cancer therapy[M]//Issel-bacher KJ.Harrison s principles of internal medicine.14 th ed.New York:McGraw-Hill,1988:523-537.
[4]Speake G,Holloway B.Costello G.Recent developments related to the EGFR as a target for cancer chemotherapy[J].Curr Opin Pharmacol,2005,5(4):343-349.
[5]Johnson GL.Dohlman HG.Graves LM.MAPK kinase kinases(MKKKs)as a target class for small-molecule inhibition to modulate signaling networks and gene expression[J].Curt Opin ChemBiol,2005,9(3):325-331.
[6]Mitsiades CS,Mitsiades N,Koutsilieris M,et al.The Akt pathway:molecular targets for anti-cancer drug development[J].Curr cancer Drug Targets,2004,4(3):235-256.
[7]Muller AJ,Young JC,Pendergast AM,et al.BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase onco-gene of Philadepia chromosome-posi-tive human leukemias[J].Mol Cell Biol,1991,11(4):1785-1792.
[8]Deininger MW,Goldman JM,Melo JV.The molecular biology of chronic myeloid leukemia[J].Blood,2000,96(10):3343-3356.
[9]Gorre ME,Mohammed M,Ellwood K et al.Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or anl-plification[J].Science,2001,293(5531):876-880.
[10]Adjei AA,Molina JR,Mandrekar SJ,et al.Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer[J].Clin Cancer Res.2007,13(9):2684-691.
[11]Wolter P,Dumez H,Schtffski P.Sunitinib and hypothyroidism[J].N Engl J Med,2007,356(15):1580.
[12]Tsuchiya M,Asada A,Maeda K,Ueda Y,Sato EF,Shindo M,Inoue M:Propofol versus midazolam regarding their antioxidant activities.Am J Respir Crit Care Med 2001,163:26-31.
[13]Kanaya N,Gable B,Murray PA,Damron DS:Propofol increases phosphorylation of troponin 1 and myosin light chain 2 via protein kinase C activation in cardiomyocytes.Anesthesiology 2003,98:1363-1371.
[14]Tsuchiya M,Asada A,Arita K,Utsumi T,Yoshida T,Sato EF,Utsumi K,Inoue M:Induction and mechanism of apoptotic cell death by propofoi in HL-60 cells.Acta Anaesthesiol Scand 2002;46:1068-1074.
[15]Rafat A Siddiqui,Mustapha Zerouga,Min Wu,et al:Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells.Breast Cancer Research 2005,7:R645-R654.
[16]陆永奎,胡晓桦,李永强,等。以紫杉醇为主的联合化疗方案治疗转移性乳腺癌的临床研究[J].现代肿瘤医学,2006,14(3):279-281.
[17]胥彬。抗癌药物研究的新进展[J].实用肿瘤杂志,2001,16(5):289-291.
[18]Broker LE,HuismanC,Span SW,et al.Cathepsin B hiediales caspase-independent cell death induced by micmtubule slabilizing agents in non-small cell lung cancer cells[J].Cancer Res,2004,64(1):27-30.
[19]DiLeo A.The European experience with docetaxel in the treatment of early-stage breast cancer[J].Clin Breast Cancer,2002,3(suppl 2):S59-62.
[20]Steams V,Singh B,Tsangaris T,et al.A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer[J].Clin Cancer Res,2003,9(1):124-133.
[21]SudaT,Takahashi T,Golstein P,et al.Moleculor Cloning and expression of the Fas ligand,a novel member of the tumor necrosis factor family[J].Cell,1993,75(6):1169-1178.
[22]Gebbia V, Blasi L, Borsellino N, et al. Paclitaxel and epidox orubicin or doxorubicin versus cyclophosphamide and epidox orubicin as first-line chemot chemotherapy for metastatic breast carcinoma: a randomised phase II study [J]. Anticancer Res, 2003, 23 (IB): 765-771.
[1]Bowman LC,Hancock MI,Santana VM,et al.Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma.,the St- Jude Children's Research Hospital experience,1962 to 1988[J],J Clin Oncol,1991,9:1599.
[2]高解春.小儿晚期恶性肿瘤延期和二次手术的指征和时机[J].中华小儿外科杂志,1995,16:295.
[3][3]江启俊.外科治疗神经母细胞瘤的世纪回顾及展望[J].中华小儿外科杂志,2000,21:137.
[4]凯,高解春.神经母细胞瘤的治疗进展[J].中华小儿外科科杂志,2002,23:169.
[5]Ikuta K.Cord blood stem cell transplantation and cord blood bank[J].Nippon Rinsho,1998,56(2):521.
[6]Ferrari N,Pfahl M,Levi G,et al.Retinoic acid receptor gammal(RAR)levels control RARbeta2 expression in SK-N-BE2 neuroblastoma cells and regulate a differentiation apoptosis switch[J].Mol Cell Biol,1998,18:6482.
[7]Moore TB,Koeffer HP,Yamashiro JM,et al.Vitamin D3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells[J].Clin Exp Metastasis,1996,14(3):239.
[8]Lorence RM,Reichard KW,Katubig BB,et al.Cornplete regression of human neuroblastoma xenografts in athymic mice after local newcastle disease Virus,ther-apy[J].J Natl Cancer Inst,1994,86(16):1228.
[9]Evans AE,Silber JH,Shpilsky A,et al.Successful management of low-stage neuroblastoma without adjuvant therapies:a comparison of two decades,1972through 1981 and 1982 through 1992,in a single institution[J].J Clin Oncol,1996,14(9):2504.
[10]Marsh JW,Geller DA,Finkelstein SD,et al.Role of liver transplantation for hepatobiliary malignant disorders[J].Oncology,2004,5(8):480-488.
[11]钦伦秀,孙惠川,汤钊猷.原发性肝癌研究进展[J].China J Surg,2006.44(15): 1070.
[12]Eaton DL,Kamsdell HS.Species and diet related diferences in plied mycology [M].V01 V.New York:Academic Press,1991.322.
[13]汤钊猷,余业勤.原发性肝癌[M].上海:上海科学技术出版社。1999.334.
[14]龚国忠,蒋永芳,朱映华.丙型肝炎病毒Ns 5A对p53活性调控机制研究[J].中华肝脏病杂志,2003,11(3):162.
[15]俞顺章,赵宁,资晓林.饮水中微囊藻毒素与我国原发性肝癌关系的研[J].中华肿瘤杂志,2001,23(2):96。
[16]Tran TT,Nissen N,Poordad FF,et al,Advances in liver transplantation.New strategies and current care expand access,enhance survival[J].Postgrad Med,2004,115(5):73-76.
[17]吴孟超,陈汉,沈峰.原发性肝癌的外科治疗.附5524例报告[J].中华外科杂志,2001,39(1):25-28。
[18]Schwarz RE,Smith DD.Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population[J].Am J Surg,2008,4(22):
[1]王红阳,丁劲,冯赘。中国肿瘤生物治疗杂志,Vol.14 No.5 Oet.2007,401-404。
[2]孙燕.积极提高医学临床研究的质量.中华肿瘤防治杂志.2006;13(2):81-83。
[3]储大同.肿瘤分子靶向治疗的进展及问题.临床肿瘤学杂志2006;11:1-6。
[4]Westerhoff HV,Palsson B0.The evolution of molecular biology into systems biology[J].Nat Biotechnol,2004,22(10):1249-1252.
[5]Wolf B,Brischwein M,Lob V.Cellular signaling.,aspects for tumor diagnosis and therapy[J].Biomed Yech(Berl),2007,52(1):164-168.
[6]Binetruy B,Heasley L,Bast F,et al.Concise review.,regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases[J].Stem Cells,2007,25(5):1090-1095.
[7]Huang C,Jacobson K,Schaller MD.MAP kinases and cell migration[J].J Cell Sci,2004,1179(20):4619-4628.
[8]Wu WS.The signaling mechanism of ROS in tumor progression[J].Cancer Metastasis Rev,2006,25(4):695-705.
[9]Polakis P.Wnt signaling and cancer[J].Genes Dev,2000,14:1837-1851.
[10]Lustig B,Behrens J.The Writ signaling pathway and its role in tumor development [J].J Cancer Res Clin Oncol,2003.129(4):199-221.
[11]Major MB,Camp ND,Berndt JD,et al.Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling[J],science,2007,316(5827):1043-1046.
[12]Perkins ND.Integrating cell-signalling pathways with NF-kappaB and IKK function[J].Nat Rev Mol Cell Biol,2007,8(1):49-62.
[13]Schulze-Luehrmann J,Ghosh S.Antigen-receptor signaling to nuclear factor kappa B[J].Immunity,2006,25(5):701-715.
[14]Derynck R,Akhurst RJ,Balmain A.TGF-beta signaling in tumor suppression and cancer progression[J].Nat Genet,2001,29(2):117-129.
[15]Slapak CA,Kufe DW.Principles of cancer therapy[M]//Issel-bacher KJ.Harrison's principles of internal medicine.14 th ed.New York:McGraw-Hill, 1988:523-537.
[16]Motzer JR,Hutson TE,Tomczak P,et al.Phase Ⅲ rand omized trial of sunitinib malate(SU1 1 2 4 8)ver su s interferon-alfa(IFN-α)a s first-1 in esys temic the rapy for patients with metastatic rena 1 cell carcinoma(mRCC)Proc ASCO 2005;24:LBA36.
[17]孙燕、何友兼、许立功,等.美罗华治疗B细胞淋巴瘤Ⅱ期临床验证报告。中国新药杂志1999;8(12):822-4.
[18]孙燕、李丽庆、宋三泰,等.注射用曲妥珠单抗治疗晚期乳腺癌临床验证报告。中华肿瘤杂志2003:25:581-3.
[19]Kumar R,Shepard HM,Mendelsohn J.Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoelonal antibody and serum growth factor(s)in human mammary carcinoma cells[J].Mol Cell Biol,1991,11(2):979-986.
[20]Molina MA,Codony-Servat J,Albanell J,et al.Trastuzumab(herceptin),a humanized anti-Her2 receptor monoclonal antibody,inhibits basal and activated Her2 ectod-omain cleavage in breast cancer cells[J].Cancer Res,2001,61(12):4744-4749.
[21]Pieeart-Gebha rt MJ,Protcer M,Leyland-Jones B,et al.Trastuzum abafter adjuvant chemo therapy in HER2-positive breast cancer.New Engl J Med2005;353(16):1660-72.
[22]Lin NU,Carey LA,Liu MC,e t al.Phase Ⅱ trial ofla p at in ib for b rainme s tatas es in patients with HER2+ breast cancer.Pr oc ASCO 2006;24:503a.
[23]Kelly H,Gold berg RM.Systemic therapy for metastatic co lo rectal cancer:current options,current evidence.J Clin Onco 12005 Ju 110;23(20):4553-60.
[24]J.B.Vermorken,J.Bourhis,J.Trigo,et a l.Cetuximab in re-current/metastatic (R&M)squamous cell carcinoma of the head and neck(SCCHN)refractory to first -line platinum-based therapies.Proc Am Soc Cl in On col2005;23(16s):5505.
[25]王华庆、沈芸.分子靶向药物贝伐单抗研究进展。中国肿瘤2005;14:716-9.
[26]Berry SR,Cunningham D,Michail M,e t al.Preliminary safety of bevacizumab with first-line Folfox,Capox,F olfe ri an d cap ec ta b in e for mCRC-First BRA trial.Proc ASCO 2006;24:3534a.
[27]Deininger MW,Goldman JM,Lydon N,et al.The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells[J].Blood.1997,90(9):3691-3698.
[28]Druker BJ,Sawyers CL,Kantarjian H et al.Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome[J].N Engl J Med,2001,34(14)1038-1042.
[29]Kantarjian HM.Cortes JE.O Brien S et al.Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferonalpha[J].Blood,2004,104(7):1979.1988
[30]王金万、孙燕、刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC 随机、双盲、对照、多中心Ⅲ期临床研究。中国肺癌杂志2005;8:283-290.
[31]张芷旋,周清华.中药抗肺癌血管生成药物的研究进展.中国肺癌杂志,2006:96-99.
[32]Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoelonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,34(11):783-792.
[33]van't Veer LJ,Dai H,van de Vijver MJ,et al.Gene expression profiling predicts clinical outcome of breast cancer[J].Nature,2002,415(6871):530-536.